# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger ...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milest...
GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote
Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the compa...
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to st...
Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S.
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Tryp Therapeutics Inc. (OTCQB: TRYPF) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infu...